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Abstract The reversible combination of a ligand with speciﬁc sites on the surface of a receptor is one of the most
important processes in biochemistry. A classic equation with a useful simple graphical method was
introduced to obtain the equilibrium constant, Kd, and the maximum density of receptors, Bmax. The
entire 125I-labeled ligand binding experiment includes three parts: the radiolabeling, cell saturation
binding assays and the data analysis. The assay format described here is quick, simple, inexpensive, and
effective, and provides a gold standard for the quantiﬁcation of ligand-receptor interactions. Although
the binding assays and quantitative analysis have not changed dramatically compared to the original
methods, we integrate all the parts to calculate the parameters in one concise protocol and adjust many
details according to our experience. In every step, several optional methods are provided to accom-
modate different experimental conditions. All these reﬁnements make the whole protocol more
understandable and user-friendly. In general, the experiment takes one person less than 8 h to com-
plete, and the data analysis could be accomplished within 2 h.
Keywords Equilibrium constant, Maximum density of receptors, Saturation binding assays, I-125 labeling,
Radioligand
INTRODUCTION
Research on receptors has developed very quickly in the
past few decades. The interactions between ligands and
receptors generate and enhance signals for recognition,
feedback and crosstalk in cells (Klotz 1985; Wilkinson
2004). Receptors are divided into two groups by their
location: in the membrane or the nucleus. Hormones
and transmitters can selectively recognize and bind to
receptors to accomplish a biological process. Many
drugs are designed and improved based on utilizing the
ligand-receptor interaction.
Radioligand binding is widely used to deﬁne receptor
function at the molecular level. The ﬁrst radiolabeled
binding assay was developed during the 1960s (Maguire
et al. 2012). This radioligand binding assay (RBA)
remains the most sensitive quantitative approach to
measuring binding parameters in vitro, even in low
receptor-expression cells (Rovati 1993; Keen 1995).
Since the 1970s, the application of RBA has developed
rapidly, with better receptor preparations, more radio-
labeled ligands and higher radioactivity. Currently,
appropriate ligands radiolabeled with tritium or iodine
are available for the study of many receptors, including
adrenergic, cholinergic, dopaminergic, serotonergic, and
opiate receptors (Tallarida et al. 1988). This widespread
availability has led to a rapid growth in the use of radi-
oligand binding assays to characterize novel receptors
and receptor subtypes and determine their anatomical
distribution, and these assays play a vital role in the
development of drugs by the pharmaceutical industry
(Bylund and Toews 1993; Carpenter et al. 2002).
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Unlabeled ligands require a radioactive isotope to be
incorporated into the molecule. It is occasionally nec-
essary to modify the structure of the ligands to provide
a suitable site for radiolabeling. However, it is imper-
ative that the selectivity and speciﬁcity of the ligand be
retained after the modiﬁcation and radiolabeling. Two
basic parameters of this binding site can be studied by
kinetic and saturation analysis: the afﬁnity of the
ligand for its recognition site, the Kd, and an estimate
of the number of binding sites in a given tissue, the
Bmax (Williams and Jacobson 1990). The Kd is the
equilibrium dissociation constant, which is the con-
centration of ligand that will occupy 50% of the
receptors. The generally accepted standard is that a
ligand-receptor binding with a Kd of 1 nmol/L or less
has a high afﬁnity, whereas ligands binding with a Kd
of 1 lmol/L or more have low afﬁnity (Davenport and
Russell 1996). Bmax signiﬁes the maximum density of
receptors. This value is unique to a particular tissue in
the binding assay, and it is usually corrected using the
amount of protein or cells present.
MECHANISM OF ACTION
Analysis of radioligand binding experiments is based
on a simple model; the law of mass action that
describes the interaction between one molecule of
ligand and one receptor molecule. For example, a
neurotransmitter binds to the synaptic receptor to
initiate the neurobiological process, or an antibody
binds to an antigen to initiate the immunological
response. In the simplest and most common case, this
is a bimolecular reaction between a ligand and a
receptor. This model assumes that binding is reversible
(Anderson 1994).
R½  þ L½  RL½ ; ð1Þ
where [R] is the concentration of free receptor, [L] is the
concentration of free ligand, [RL] is the concentration of
the complex, k1 is the association rate constant, and k2 is
the dissociation rate constant,
Kd ¼ k2k1 ¼
½R½L
½RL : ð2Þ
The density of unbound receptors [R] and ligands [L]
cannot be determined but could be given:
R½  ¼ RL½   RL½ : ð3Þ








For further analysis, [SB] could represent the con-
centration of ligand bound to the receptor, [F] repre-
sents the concentration of unbound ligand or ‘‘free’’
ligand, and Bmax represents the greatest attainable








Thus, a plot of fractional [SB]/[F] vs. [RL] will give
the basic information of the ligand-receptor interac-
tions, known as a ‘‘Scatchard plot’’. An alternative is the









Radioligand-binding techniques are applicable to any
receptor of interest, provided it has a relative ligand that
could selectively bind the receptor and be labeled with
radioactive isotopes. Antibodies, proteins and peptides
that contain Tyr could easily be labeled with iodine.
Radioligands provide precise probes to quantify the
initial interaction between ligands and receptors. For
example, the kinetics of the association and dissociation
of radioligands can be accurately examined from a
simple tissue expressing the speciﬁc target receptors. A
series of concentrations of unlabeled ligands could
inhibit the forces established between radioligands and
receptors, which could be used to measure the equi-
librium dissociation constants. Radioligand binding also
permits a characterization of receptor subtypes with
different afﬁnities and provides an estimate of their
relative proportions, especially in the study of central
nervous system receptors, where the effects of neuro-
transmitters are complex, and isolated tissue prepara-
tions are unfeasible (Tallarida et al. 1988). Radioligand
binding assays can also be used to monitor the changes
in receptor density, perhaps resulting from the patho-
logical conditions of pharmacological intervention.
Furthermore, the Scatchard plot is a useful diagnostic
tool to determine whether more than one ligand mole-
cules bind to a single receptor (Hollemans and Bertina
1975; Rovati 1998). A concave upward plot is indicative
of nonspeciﬁc binding, negative cooperativity, or multi-
ple classes of binding sites. A concave downward plot
suggests either positive cooperativity or instability of
the ligand (Wilkinson 2004).
However, binding parameters could be affected by
many factors including the speciﬁc radioactivity, the
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type and ionic strength of the buffer, the presence of
divalent ions and the temperature. The results are not
sufﬁcient to reﬂect the real physiological response
mediated by the receptor in this homogenate prepara-
tion, such as minimizing degradation of the ligand
(Davenport and Russell 1996). In addition, radioligand-
binding assays cannot adequately discriminate between
full agonists that elicit maximal physiological responses
and partial agonists that cannot elicit a maximal
response (Tallarida et al. 1988).
SUMMARIZED PROCEDURE
1 Dissolve iodogen in chloroform at a concentration
of 2 mg/mL, evaporate the chloroform and make
the iodogen-coated tube under an N2 stream.
2 Dissolve Protein L in 0.2 mol/L phosphate buffer
(pH 7.4) at a concentration of *2 mg/mL.
3 Mix 50 lL Protein L, 50 lL PB (0.2 mol/L, pH 7.4)
and 50–100 lL Na125I ([40 MBq) in an
iodegen-coated tube. Incubate for 7–8 min at
room temperature.
4 Remove the reaction mixture from the iodogen
tube and purify the radiolabeled protein by size
exclusion chromatography using a PD MidiTrap
G-25 column.
5 Count the activity in the ﬁnal recovered tube and
calculate the speciﬁc activity.
6 Wash two 96-well plates with pre-cooled cell-
binding buffer for three times (100 lL each well)
and use the vacuum manifold to remove the buffer.
Place two 96-well plates for speciﬁc binding and
non-speciﬁc binding respectively.
7 From a stock of two million receptor-
overexpressed cells per mL of cell-binding buffer
(total volume [ 1.5 mL), add 1 9 105 cells
(50 lL) each well in the 96-well plate.
8 Prepare three stock solutions of different concen-
tration 125I-Protein L (e.g., 0.1, 1 and 10 lg/mL) in
cell-binding buffer.
9 Add the cells and 125I labeled ligand into the
plates according to calculation of ﬁnal concentra-
tion for each well (N = 4), and adjust the total
volume to 200 lL per well with cell-binding buffer
and incubate for 2 h at 4 C.
10 Use the vacuum manifold to remove the incuba-
tion buffer from the plates and wash 5–10 times
with cell-binding buffer (100 lL/well).
11 Heat-dry the plates in the dry bath incubator, and
collect the membrane from each well into poly-
styrene culture test tubes.
12 Add 4–7 tubes of standard samples to measure.
Then measure the radioactivity on each mem-
brane with a c-counter.
13 For each experimental measurement, subtract the
cpm values of groups. Added activities [TA], total
binding activities [TB] and non-speciﬁc binding
activities [NSB] could be measured and calculated
by the activities on the membranes of plates.
14 Calculate [SB], [LT], [RL], [L] and [F] using these
corrected values.
15 Kd value and Bmax could be calculated by Scatchard
Plot, Woolf Plot or the software.
PROCEDURE
Radiolabeled protein preparation [TIMING] ~1 h
1 There are two options for labeling the proteins.
(A) Option A: Chloramine-T method (Hunter
1970; Opresko et al. 1980).
i. Dissolve Protein L (see ‘‘Reagent setup’’ sec-
tion) in 0.2 mol/L phosphate buffer (pH 7.4)
at a concentration of 2 mg/mL.
ii. Mix the following reagents: 50 lL Protein L,
50–100 lL Na125I ([40 MBq) and 100 lg
Chloramine-T (1 mg/mL in 100 lL 0.2 mol/L
PB, pH 7.4). Incubate for 40 s at room
temperature.
[CRITICAL STEP] It is highly recommended to
limit the reaction time in 1–3 min.
iii. Add 100 lL Na2S2O5 (200 lg in ddH2O) and
100 lL 1% KI (1 mg in ddH2O) to the mixture.
(B) Option B: Iodogen method (Bailey 1996).
i. Dissolve Protein L (see ‘‘Reagent setup’’ sec-
tion) in 0.2 mol/L phosphate buffer (pH 7.4)
at a concentration of *2 mg/mL.
ii. Dissolve iodogen in chloroform at a concen-
tration of 2 mg/mL. Transfer aliquots of
25 lL (50 lg) to a glass-bottomed screw cap
vial. Evaporate the chloroform to dryness
under an N2 stream, leaving a thin coating of
iodogen in the tube. Store the desiccated
iodogen-coated tubes at -20 C until
required for iodination.
iii. Mix 50 lL Protein L, 50 lL PB (0.2 mol/L, pH
7.4) and 50–100 lL Na125I ([40 MBq) in an
iodogen-coated tube. Incubate for 7–8 min at
room temperature.
[CRITICAL STEP] It is highly recommended
to maintain the duration of the reaction
between 5–10 min.
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iv. Remove the reaction mixture from the iodo-
gen tube and apply to purifying.
[CAUTION!] It is imperative to obtain appro-
priate training from the institutional radiation
safety ofﬁce before experimenting with
radioactivity. Abide by all relevant regulatory
rules and use appropriate protection when
handling radioactivity. Dispose of the 125I-
containing radioactive waste according to the
institutional radioactive waste disposal
guidelines.
2 Puriﬁcation: Purify the radiolabeled protein by size
exclusion chromatography using a PD MidiTrap
G-25 column.
(A) Preparation and equilibration: Remove the
caps and the storage solution. Fill the column
with PBS and discard the ﬂow-through.
Repeat this procedure twice (three times in
total).
(B) Sample application: Add a maximum of
1.0 mL of sample to the column. Apply the
sample slowly in the middle of the packed bed
and discard the ﬂow through.
(C) Elution: Place a clean tube for sample collec-
tion under the column. Elute with 1.5 mL PBS
and collect the products.
3 Count the activity in the ﬁnal recovered tube. The
speciﬁc activity is calculated as the quotient
between the recovered activity and the total amount
of protein. This calculation assumes that 100% of
the protein added to the iodination was recovered,
which is not typical. (Analytical Techniques, T.P.
Mommson)
Specific activity ¼ Radioactivity
Protein mass
(Ci/g):
[CRITICAL STEP] To obtain an optimal result, it is
sufﬁcient to utilize radioligands with high speciﬁc
activity ([20 Ci/mmol).
Saturation binding [TIMING] 5–7 h
4 Wash two 96-well plates with pre-cooled cell-
binding buffer three times (100 lL each well) and
use the vacuum manifold to remove the buffer.
One 96-well plate (Plate A) will be used for
speciﬁc binding and the other one (Plate B) will be
used for non-speciﬁc binding(Cai and Chen 2008).
5 From a stock of twomillion receptor-overexpressed
cells per mL of cell-binding buffer (total volume[
1.5 mL), add 1 9 105 cells (50 lL) to each well in
the 96-well plate.
6 Prepare three stock solutions of different concen-
trations of 125I-Protein L (e.g., 0.1, 1 and 10 lg/mL)
in cell-binding buffer. Typically a series of concen-
trations between 1 ng/200 lL and 1 lg/200 lL
will be needed per well.
[CAUTION!] It is imperative to obtain the appro-
priate preparatory training and abide by all regu-
latory rules when handling radioactivity.
[? TROUBLESHOOTING]
7 Add the cells and 125I-labeled ligand into Plate A
following Table 1, and adjust the total volume to
200 lL per well with cell-binding buffer and
incubate for 2 h at 4 8C. More than four samples
are recommended for each concentration.
[? TROUBLESHOOTING]
8 Add the cells, 125I-labeled ligands and excess cold
Protein L into Plate B following Table 2, and adjust
the total volume to 200 lL per well with cell-
binding buffer and incubate for 2 h at 4 8C as the
last step. More than four samples are recom-
mended for each concentration.
[? TROUBLESHOOTING]
9 Use the vacuum manifold to remove the incuba-
tion buffer from the 96-well plate and wash 5–10
times with cell-binding buffer (100 lL per well).
10 Heat-dry the 96-well plates in a dry bath incuba-
tor until all ﬁlter membranes are dry. This usually
takes approximately 15 min.
Table 1 Sample adding
strategy in the typical 96-well
plate for the speciﬁc binding
assay
Speciﬁc binding group
No. 1 2 3 4 5 6 7 8 9 10 11 12
125I-Protein L (lg/mL) 0.1 0.1 0.1 0.1 1 1 1 1 10 10 10 10
125I-Protein L (lL) 10 20 50 80 10 20 50 80 10 20 50 80
Binding buffer (lL) 140 130 100 70 140 130 100 70 140 130 100 70
Cell solution (lL) 50 50 50 50 50 50 50 50 50 50 50 50
Total volume (lL) 200 200 200 200 200 200 200 200 200 200 200 200
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11 Collect the membrane from each well into poly-
styrene culture test tubes.
12 Add 4–7 tubes of radiolabeled samples (standard
samples) to measure.
[PAUSE POINT] The radioactivity on each mem-
brane can be measured later, because 125I has a
half-life of 60 d.
13 Measure the radioactivity on each membrane with
a c-counter.
Analysis [TIMING] 1–2 h
14 For each experimental measurement, subtract the
cpm values of the groups. Added activities [TA]
could be measured using the standard samples.
Total binding activities [TB] and non-speciﬁc
binding activities [NSB] could be measured by the
activities on the membranes of Plate A and B,
respectively.
15 Using Eqs. (5)–(9), calculate [SB], [LT], [RL],
[L] and [F] using these corrected values:
SB½  ¼ TB½   NSB½ ; ð7Þ
½LT ¼ ½TAðcpmÞ
E% ½SAðlCi=nmolÞ  2:22 106
 10
3
Volume ðLÞ pmol=Lð Þ; ð8Þ
½RL ¼ ½SBðcpmÞ
E% ½SAðlCi=nmolÞ  2:22 106
 10
3
Volume ðLÞ pmol=Lð Þ; ð9Þ
L½  ¼ LT½   RL½ ; ð10Þ
F½  ¼ TA½   SB½ : ð11Þ
16 Kd and Bmax could be calculated using a Scatchard
plot, Woolf plot or the software.
(A) Option A: Scatchard plot
i. For each point on the concentration, enter
[RL] into the X column and the value of








ii. All the points are plotted and then linear
regression is used to produce the line.
iii. Referring to the Results sheet for the
regression analysis, the X- and Y-axis inter-
cepts could be calculated. The X-intercept
represents the Bmax, and the Y-intercept
represents Bmax/Kd.
(B) Option B: Woolf plot
i. For each point on the concentration, enter
[L] into the X column and the value of [F]/








ii. All the points are plotted and then linear
regression is used to produce the line.
iii. Referring to the results sheet for the regres-
sion analysis, theX- andY-axis intercepts could
be calculated. The X-intercept represents the
Kd, and the Y-intercept represents Kd/Bmax.
(C) Option C: Saturation binding curve
i. Create a new project (ﬁle) on Prism(Motul-
sky 1996). For each point on the saturation-
binding curve, enter the concentration of
ligand into the X column and [SB] into the
Y column.
Table 2 Sample adding
strategy in the typical 96-well
plate for the non-speciﬁc
binding assay
Non-speciﬁc binding group
No. 1 2 3 4 5 6 7 8 9 10 11 12
125I-Protein L (lg/mL) 0.1 0.1 0.1 0.1 1 1 1 1 10 10 10 10
125I-Protein L (lL) 10 20 50 80 10 20 50 80 10 20 50 80
Cold Protein L (lL) 50 50 50 50 50 50 50 50 50 50 50 50
Binding buffer (lL) 90 80 50 20 90 80 50 20 90 80 50 20
Cell solution (lL) 50 50 50 50 50 50 50 50 50 50 50 50
Total volume (lL) 200 200 200 200 200 200 200 200 200 200 200 200
PROTOCOL C. Dong et al.
152 | December 2015 | Volume 1 | Issue 3  The Author(s) 2016. This article is published with open access at Springerlink.com
ii. Select ‘‘One site binding’’ under the ‘‘Nonlin-
ear Regression dialog’’ box to analyze the
data and produce a binding curve.
iii. Prism displays the best-ﬁt values (Bmax and
Kd) for the binding parameters in the results
sheets.
[TIMING]
Step 1–3 Preparation of the 125I-Protein L and cold
ligands takes approximately 1 h.
Step 4–6 Preparation of the receptor samples takes
approximately 1 h.
Step 7–13 The cell-binding assay usually takes
4–6 h, depending on how many samples
are used.
Step 13–16 Activity measurements and data analyses
take approximately 1–2 h.
[? TROUBLESHOOTING]
Step 6 The presence of certain metal ions (e.g., Mn2?
and Mg2?) in the cell-binding buffer is
essential for receptor binding. Binding buffer
without these ions will result in low counts
from the collected membrane.
Step 7 It is necessary to add the cells and buffer with
multiple-channel pipettes to reduce the time of
this step. It takes practice to become skilled at
adding serial concentrations of radioligand and
cold ligand. It is important to stay focused and
patient.
Step 8 The non-speciﬁc binding assay requires a large
quantityof the cold ligand.Usually the ligandsare
difﬁcult to prepare or very expensive. The
Scatchard plot and the Woolf plot could be
completed using fewer concentrations and fewer
parallel samples. In total, about 20 samples are
sufﬁcient for ﬁtting the linear regression.
ANTICIPATED RESULTS
Figures 1 and 2 present typical representative data
obtained using the method described here. EGFR over-
expressing UM-SCC-22B cells were assayed against the
radiolabeled antibody 125I-Nimotuzumab. The labeling
yield of 125I-Nimotuzumab was 97.6% and the radio-
chemical purity was[98.5% after puriﬁcation (Fig. 1).
The speciﬁc activity was 24.7 Ci/g.
Figure 2A shows an example of a typical equilibrium
saturation curve using the radiolabeled assay with
increasing concentrations of 125I-Nimotuzumab. Fig-
ure 2B shows a typical ‘‘Scatchard plot’’. Figure 2C
shows a typical ‘‘Woolf plot’’. In parallel comparisons
from the same data obtained from the binding assays,
the Scatchard plot, the Woolf plot and the saturation
radioligand-binding curve gave similar estimates of the
Kd (7.81, 7.935 and 8.095 pL/mol, respectively) and
Bmax (113.4, 114.5 and 115.3 pmol/L) (Table 3). The
average total number of EGF receptors on each UM-SCC-
22B cell could be calculated:






• 0.2 mol/L phosphate buffer, pH 7.4 (NaH2PO42H2O
0.4063 g, Na2HPO412H2O 5.8077 g in 200 mL
ddH2O)
• Chloramine-T (100 lg in 0.2 mol/L PB)
• Na2S2O5 (200 lg in 100 lL ddH2O)
• KI (1 mg in 100 lL ddH2O)
• Chloroform















0                     50                    100                 150                  200
0                      50                  100                  150                 200
Fig. 1 ITLC analysis of 125I-labeled Nimotuzumab. The labeling
yield of 125I-Nimotuzumab was 97.6%, and the radiochemical
purity was 98.5% after puriﬁcation
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• Cell-binding buffer (20 mmol/L Tris, 150 mmol/L
NaCl, 2 mmol/L CaCl2, 1 mmol/L MnCl2, 1 mmol/L
MgCl2, 1% (wt/vol) bovine serum albumin; pH 7.4)
• PBS buffer (NaH2PO42H2O 0.24 g, Na2HPO412H2O
2.901 g and NaCl 8.5 g in 1 L ddH2O)
• Receptor-overexpressed cells (see ‘‘Reagent setup’’
section)
• Medium
• Fetal bovine serum
• Na125I (Perkin Elmer, Waltham, MA, USA)
Equipment
• pH paper (Aladdin Inc.)
• PD MidiTrap G-25 column (GE Healthcare, cat. no.
28-9180-08)
• MultiScreenTM Vacuum Manifold 96-well plate (Mil-
lipore, cat. no. MAVM0960R)
• Vacuum pump (Zhengzhou Greatwall Inc., SHB-III)
• Dry bath incubator (Fisher Scientiﬁc, cat. no. 11-718-
2)
• c-counter (PerkinElmer, 2470 automatic gamma
counter)
• Glass-bottomed screw cap vial (Agilent Technologies,
cat. no. 5182-0715)
• GraphPad Prism (GraphPad Software Inc.)
Reagent setup
Cell sample preparation Culture receptor-overexpressed
cells in corresponding medium under certain condi-
tions. Collect the cells from the ﬂasks or the plates. At
least 105 cells are needed for each well. It takes 96 wells
to test the binding of one ligand with its receptor. Wash
the cell solution with 0.01 mol/L sterile PBS three
times. Carefully resuspend the cells in cell binding
buffer to a concentration of 2 9 106 cells/mL.
Cold protein L preparation 500 mg of protein L is
dissolved in or diluted with 2.5 mL cell binding buffer.
However, it takes a large amount of ligand to ﬁnish the
experiment. In general, the cold ligands should be 1000
times more concentrated than the radiolabeled ligand to
block the receptors. Fewer cold ligands could be used in
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Fig. 2 The calculation of Kd and Bmax by Scatchard plot (A), Woolf plot (B) or the software (C)
Table 3 Comparison of the results obtained by three plots
Scatchard plot Woolf plot Saturation binding curve
Kd 7.81 7.935 8.095
Bmax 113.4 114.5 115.3
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example, eight concentrations) could conserve many
ligands.
Equipment setup
c-counter E% could be determined by comparison
between the detected cpm value and the objective cpm
value.
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